Clinical Trial

NADIM II: Neo-Adjuvant Immunotherapy

Study acronym: NADIMII
Active, Not Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
This is an open-label, randomised, two-arm, phase II, multi-centre clinical trial. 90 patients will be enrolled in this trial to examine the pathological Complete Response defined as the absence of residual tumor in lung and lymph nodes comparing patients treated with chemo-immunotherapy versus chemotherapy alone.
Protocol Amendment History 17 amendments
This ClinicalTrials.gov record has been amended 17 times since 2019-02-08; most recent amendment 2026-04-29.
Status change: Recruiting → Active, Not Recruiting 2022-05-04
Status change: Not Yet Recruiting → Recruiting 2019-06-13
Trial Details
NCT Number NCT03838159
Lead Sponsor Fundación GECP
Conditions Non Small Cell Lung Cancer
Enrollment 90 participants
Start Date 2019-05-15
Primary Completion 2027-11-30 (estimated)
Study Completion 2028-11-30 (estimated)
Updated on ClinicalTrials.gov 2026-04-30